fouremm - "It would also be nice to know, as Don would, what the potential financial opportunities are." Over the years there have been many guesses about potential sales of APB from the cardio point of view, anywhere up to multiple billions. When you add in all or some of the other potential opportunities for APB like CKD, Liver, Lung, Brain and on and on and then add COVID it looks to me like the financial opportunities are quite large. The big question we all have is, will this company survive long enough for any of those area's of potential to be exploited?

As far as this COVID trial goes it looks to me like the focus is going to be on those that are aged with co-morbidities. From the Worldometers.info site it looks like there has been over 88 million people in the USA alone that have already had COVID. One of our posters posted an article on this board a within the last 2 weeks that suggested 50% to 80% of people who have had COVID will experience some form of "long COVID". That to me looks to be yet another huge financial opportunity. The big question still remains though, will this company survive long enough to exploit the opportunities available to them?

I like the data coming in that suggests Paxlovid is not as effective as was thought originally. That at least gives us the opportunity to be one of the alternative therapies for treating COVID from the get go. For PFE their M/C is up $20 billion as a result Paxlovid. If that is the financial opportunity you were wondering about I think we can assume it's big for any company that can bring a safe and effective therapy for COVID to market.

tada